High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients

Background. Vitamin D has emerged as an important survival factor in patients with chronic kidney disease. Non-activated vitamin D may also have beneficial effects on bone, cardiovascular and immune functions. Cholecalciferol is the prevalent non-activated vitamin D in Europe, but there is no valid...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2008-12, Vol.23 (12), p.4016-4020
Main Authors: Tokmak, Faruk, Quack, Ivo, Schieren, Gisela, Sellin, Lorenz, Rattensperger, Dirk, Holland-Letz, Tim, Weiner, Stefan M., Rump, Lars C.
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
calcidiol
Calcifediol - blood
cholecalciferol
Cholecalciferol - administration & dosage
Cholecalciferol - adverse effects
chronic kidney disease
Drug Tolerance
Emergency and intensive care: renal failure. Dialysis management
Female
General and cellular metabolism. Vitamins
haemodialysis
Humans
Intensive care medicine
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Male
Medical sciences
Pharmacology. Drug treatments
Prospective Studies
Renal Dialysis - adverse effects
vitamin D
Vitamin D Deficiency - blood
Vitamin D Deficiency - drug therapy
Vitamin D Deficiency - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Vitamin D has emerged as an important survival factor in patients with chronic kidney disease. Non-activated vitamin D may also have beneficial effects on bone, cardiovascular and immune functions. Cholecalciferol is the prevalent non-activated vitamin D in Europe, but there is no valid prospective data available about its use in haemodialysis patients. Thus, we initiated a prospective study to evaluate dosing, safety and tolerability of cholecalciferol supplementation in haemodialysis patients. Methods. The prospective study included 64 haemodialysis patients. During replenishment phase patients received 20 000 IU cholecalciferol/week for 9 months. In the open maintenance phase (15 months), patients were randomized to a treated group (20 000 IU cholecalciferol/month) and an untreated group, which did not receive cholecalciferol. Results. Calcidiol [25(OH)D] deficiency (30 μg/l; K/DOQI) were achieved in 57% of patients. Calcium increased from 2.28 ± 0.17 to 2.37 ± 0.19 mmol/l (9.1 ± 0.69 mg/dl to 9.49 ± 0.75 mg/dl) (P
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfn367